{
  "submission_file": "src/content/submissions/2026-02/2026-02-24T09-14-53Z_mercks-once-daily-cholesterol-pill-matches-injecta.json",
  "article_title": "Merck's Once-Daily Cholesterol Pill Matches Injectable Efficacy in Phase 3 Trial, Opening Path to First Oral PCSK9 Inhibitor",
  "fetched_at": "2026-02-24T09:36:14.537Z",
  "sources": [
    {
      "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2511002",
      "file": null,
      "status_code": 403,
      "content_type": "text/html; charset=UTF-8",
      "content_length": null,
      "sha256": null,
      "error": "Forbidden",
      "fetched_at": "2026-02-24T09:36:14.083Z",
      "redirected_domain": null
    },
    {
      "url": "https://www.statnews.com/2025/11/08/merck-enlicitide-cholesterol-pill-study-results/",
      "file": "source-1.html",
      "status_code": 200,
      "content_type": "text/html; charset=UTF-8",
      "content_length": 181225,
      "sha256": "17d8f6fd3daf1384edd3f5c2c8b491713eb54c9d252376e40a5ecec4f87f30a4",
      "error": null,
      "fetched_at": "2026-02-24T09:36:14.103Z",
      "redirected_domain": null
    },
    {
      "url": "https://www.medscape.com/viewarticle/oral-pcsk9-inhibitor-provides-ldl-reductions-comparable-2025a1000v03",
      "file": "source-2.html",
      "status_code": 200,
      "content_type": "text/html; charset=utf-8",
      "content_length": 718611,
      "sha256": "7edd4662b8ff7a7d1ae61df164de08f2aa855e1b33c904156582403690d652d9",
      "error": null,
      "fetched_at": "2026-02-24T09:36:14.104Z",
      "redirected_domain": null
    }
  ]
}